Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Toward Improved Selectivity in Cancer Chemotherapy: The Richard and Hinda Rosenthal Foundation Award Lecture

Toward Improved Selectivity in Cancer Chemotherapy: The Richard and Hinda Rosenthal Foundation... Approaches to improving the selectivity of drugs for the treatment of patients with cancer are discussed, with emphasis on folate antagonists as prototype compounds. The use of metabolites (leucovorin, 5-methyltetrahydrofolate) as "rescue" agents following methotrexate treatment with appropriate monitoring of blood levels of methotrexate has led to the safe use of this antimetabolite in high doses and an improved therapeutic index for the use of this drug in some human cancers. The use of methotrexate in conjunction with fluorouracil administration is sequence dependent in experimental tumor models and is being tested in human tumors. New folate antagonists, designed to inhibit thymidylate synthetase per se or as facilitators of 5-fluorodeoxyuridine 5'-monophosphate binding to this enzyme are also discussed. The potential for selectivity using nonclassical folate antagonists is also illustrated; in addition to Baker's antifol (triazinate), a triazine folate antagonist, now in clinical trial, several 2,4-diaminoquinazolines were found to be potent exhibitors of DNA synthesis in human leukemic leukocytes. Drug resistance to antineoplastic agents continues to be an important clinical problem. By using resistance to methotrexate as an example, exploitation of drug-resistant mutants by design of specific inhibitors is possible. A strategy for the prevention of drug resistance is advanced, based on data derived from experimental systems. It is concluded that large doses of drugs used in intermittent fashion and sequentially in combination may be the best strategy to avoid this problem. An example of this strategy is Adriamycin-cyclophosphamide-Oncovin-methotrexate-1-ß- D -arabinofuranosylcytosine, a five-drug sequential combination used to treat diffuse histiocytic lymphoma. 1 Presented at the 1978 Meeting of the American Association for Cancer Research in Washington, D. C. Supported in part by Grants CA08010 and CA08341 and Contract NO-1-CM-33711. 2 American Cancer Society Professor of Medicine and Pharmacology. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Research American Association of Cancer Research

Toward Improved Selectivity in Cancer Chemotherapy: The Richard and Hinda Rosenthal Foundation Award Lecture

Cancer Research , Volume 39 (2 Part 1 ): 293 – Feb 1, 1979

Toward Improved Selectivity in Cancer Chemotherapy: The Richard and Hinda Rosenthal Foundation Award Lecture

Cancer Research , Volume 39 (2 Part 1 ): 293 – Feb 1, 1979

Abstract

Approaches to improving the selectivity of drugs for the treatment of patients with cancer are discussed, with emphasis on folate antagonists as prototype compounds. The use of metabolites (leucovorin, 5-methyltetrahydrofolate) as "rescue" agents following methotrexate treatment with appropriate monitoring of blood levels of methotrexate has led to the safe use of this antimetabolite in high doses and an improved therapeutic index for the use of this drug in some human cancers. The use of methotrexate in conjunction with fluorouracil administration is sequence dependent in experimental tumor models and is being tested in human tumors. New folate antagonists, designed to inhibit thymidylate synthetase per se or as facilitators of 5-fluorodeoxyuridine 5'-monophosphate binding to this enzyme are also discussed. The potential for selectivity using nonclassical folate antagonists is also illustrated; in addition to Baker's antifol (triazinate), a triazine folate antagonist, now in clinical trial, several 2,4-diaminoquinazolines were found to be potent exhibitors of DNA synthesis in human leukemic leukocytes. Drug resistance to antineoplastic agents continues to be an important clinical problem. By using resistance to methotrexate as an example, exploitation of drug-resistant mutants by design of specific inhibitors is possible. A strategy for the prevention of drug resistance is advanced, based on data derived from experimental systems. It is concluded that large doses of drugs used in intermittent fashion and sequentially in combination may be the best strategy to avoid this problem. An example of this strategy is Adriamycin-cyclophosphamide-Oncovin-methotrexate-1-ß- D -arabinofuranosylcytosine, a five-drug sequential combination used to treat diffuse histiocytic lymphoma. 1 Presented at the 1978 Meeting of the American Association for Cancer Research in Washington, D. C. Supported in part by Grants CA08010 and CA08341 and Contract NO-1-CM-33711. 2 American Cancer Society Professor of Medicine and Pharmacology.

Loading next page...
 
/lp/american-association-of-cancer-research/toward-improved-selectivity-in-cancer-chemotherapy-the-richard-and-uLtXiU09L0

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Association of Cancer Research
Copyright
Copyright © 1979 by the American Association for Cancer Research.
ISSN
0008-5472
Publisher site

Abstract

Approaches to improving the selectivity of drugs for the treatment of patients with cancer are discussed, with emphasis on folate antagonists as prototype compounds. The use of metabolites (leucovorin, 5-methyltetrahydrofolate) as "rescue" agents following methotrexate treatment with appropriate monitoring of blood levels of methotrexate has led to the safe use of this antimetabolite in high doses and an improved therapeutic index for the use of this drug in some human cancers. The use of methotrexate in conjunction with fluorouracil administration is sequence dependent in experimental tumor models and is being tested in human tumors. New folate antagonists, designed to inhibit thymidylate synthetase per se or as facilitators of 5-fluorodeoxyuridine 5'-monophosphate binding to this enzyme are also discussed. The potential for selectivity using nonclassical folate antagonists is also illustrated; in addition to Baker's antifol (triazinate), a triazine folate antagonist, now in clinical trial, several 2,4-diaminoquinazolines were found to be potent exhibitors of DNA synthesis in human leukemic leukocytes. Drug resistance to antineoplastic agents continues to be an important clinical problem. By using resistance to methotrexate as an example, exploitation of drug-resistant mutants by design of specific inhibitors is possible. A strategy for the prevention of drug resistance is advanced, based on data derived from experimental systems. It is concluded that large doses of drugs used in intermittent fashion and sequentially in combination may be the best strategy to avoid this problem. An example of this strategy is Adriamycin-cyclophosphamide-Oncovin-methotrexate-1-ß- D -arabinofuranosylcytosine, a five-drug sequential combination used to treat diffuse histiocytic lymphoma. 1 Presented at the 1978 Meeting of the American Association for Cancer Research in Washington, D. C. Supported in part by Grants CA08010 and CA08341 and Contract NO-1-CM-33711. 2 American Cancer Society Professor of Medicine and Pharmacology.

Journal

Cancer ResearchAmerican Association of Cancer Research

Published: Feb 1, 1979

There are no references for this article.